NCT Number: NCT00514254
Risk Factors for Endometrial Cancer in Black Women
RATIONALE: Learning about the risk factors for endometrial cancer in black women may help the study of endometrial cancer in the future.
PURPOSE: This clinical trial is studying risk factors for endometrial cancer in black women.
This study is active but is not currently recruiting participants.
Key information
Conditions
Age range
21 year and older
Sex eligibility
Female
Study type
Observational
Primary location
SUNY Downstate Medical Center, Brooklyn, New York, United States
About this study
OBJECTIVES:
- Establish and evaluate procedures for conducting a hospital-based case-control study of risk factors for endometrial cancer in black women.
OUTLINE: This is a multicenter study.
Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
PROJECTED ACCRUAL:
- A total of 30 cases and 30 controls will be accrued for this study.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Cases
- Diagnosed with endometrial cancer within the past year
- Self-identified as being black, African-American, black Hispanic, African, or Afro-Caribbean
- Healthy controls
- Self-identified as being black, African-American, black Hispanic, African, or Afro-Caribbean
- No history of endometrial or other cancer (except non-melanoma skin cancer)
- No prior hysterectomy
PATIENT CHARACTERISTICS:
- Speak English
- No medical condition that would make it difficult to complete the interview
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Treatment and study plan
study of socioeconomic and demographic variables
Otherevaluation of cancer risk factors
ProcedurePrimary outcomes
-
Number and percentage of potential cases and controls approached who are found to be eligible for the study and reasons for being ineligible (including language)
Time frame: 2 years
-
Number and percentage of cases and controls approached who sign informed consent
Time frame: 2 years
-
Number and percentage of cases and controls who complete each part of the study (main questionnaire, diet questionnaire, saliva/buccal specimen)
Time frame: 2 years
-
Proportion of questions with missing data
Time frame: 2 years
-
Interviewer's evaluation of interview quality and respondent cooperation
Time frame: 2 years
-
Number and percentage of cases who are willing to have tumor specimens used for future research
Time frame: 2 years
-
Characteristics of cases and controls (demographics, main risk factors, and use of health care and screening)
Time frame: 2 years
-
Proportion of participants who rate the study positively on each measure in the post-interview assessment and respondents' suggested changes to the study
Time frame: 2 years
Sponsors and collaborators
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Collaborators
- DOWNSTATE MED/KINGS CO/BKLYN
- Montefiore Medical Center
- National Cancer Institute (NCI)
- The City College of New York
Registry information
Official study title
Endometrial Cancer in Black Women
Important dates
- Study start
- 2007
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Aug 9, 2007
- Registry last updated
- Aug 12, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03526432
Endometrial Cancer, Endometrial Neoplasms
Birmingham, Alabama, United States
View Trial DetailsA Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Adnexal Diseases, Advanced Solid Tumor
La Jolla, California, United States
View Trial DetailsA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Adnexal Diseases, Advanced or Metastatic Solid Tumors
Phoenix, Arizona, United States
View Trial DetailsA Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NCT05634499
Endometrial Cancer, Endometrial Neoplasms
Little Rock, Arkansas, United States
View Trial Details